Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 6/20 | 0.81 |
| ▸ | ESR1 | P03372 | 2/20 | 0.66 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.62 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.62 |
| ▸ | TYR | P14679 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL3515847 | 0.92 | SERPINE1 (0.88) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL2791373 | 0.90 | SERPINE1 (1.00) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL29022407 | 0.89 | SERPINE1 (0.86) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL19642723 | 0.89 | SERPINE1 (0.86) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL28384704 | 0.89 | SERPINE1 (0.82) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL8382124 | 0.87 | SERPINE1 (0.79) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| Ethylene SCHEMBL16145015 | 0.86 | SERPINE1 (0.92) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL13287172 | 0.86 | SERPINE1 (0.92) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| Ethylene SCHEMBL16144939 | 0.86 | SERPINE1 (0.92) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 | |
| Ethylene SCHEMBL16144936 | 0.86 | SERPINE1 (0.92) | SERPINE1ESR1AKR1C4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559795-B2 | Compositions, methods, kits, cartridges, and systems for sequencing reagents | ILLUMINA, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20250138031-A1 | IN VITRO MEASUREMENT OF THE LYSIS OF A FIBRIN CLOT | DIAGNOSTICA STAGO (FR) | 2025-05-01 | — | — | US | claimed |
| EP-4499870-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SEQUENCING SIGNALS | Illumina, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| CN-118834553-A | Preparation method of flash rust inhibitor | 大连连昇新材料有限公司 | 2024-10-25 | — | — | CN | claimed |
| EP-4359555-A1 | COMPOSITIONS, METHODS, KITS, CARTRIDGES, AND SYSTEMS FOR SEQUENCING REAGENTS | Illumina, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117597453-A | Compositions, methods, kits, cartridges, and systems for sequencing reagents | 伊鲁米纳公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117050625-A | Water-based rust conversion coating for carbon nano tube and preparation method thereof | 铁科金化检测中心有限公司 | 2023-11-14 | — | — | CN | claimed |
| US-20230357845-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SEQUENCING SIGNALS | ILLUMINA, INC. | 2023-11-09 | — | — | US | claimed |
| WO-2023186982-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SEQUENCING SIGNALS | ILLUMINA, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| CN-113679039-B | Polyethylene glycol gallate protein carrier synergist and preparation method and application thereof | 浙江大学 | 2023-05-09 | — | — | CN | claimed |
| CN-111617035-A | Application of micelle formed by polyethylene glycol derivative in paclitaxel or derivative thereof | 天津力博生物科技有限公司 | 2020-09-04 | — | — | CN | claimed |
| CN-111423576-A | Polyethylene glycol derivative and preparation method and application thereof | 天津力博生物科技有限公司 | 2020-07-17 | — | — | CN | claimed |
| CN-106074589-A | Comprise the compositions of S S-adenosylmethionine and epicatechol gallate | 甲基化物科学国际有限公司 | 2016-11-09 | — | — | CN | claimed |
| CN-100432046-C | Activator for endogenetic pathway of coagulation and their use for exploring anomalies of coagulation | STAGO DIAGNOSTICA (FR) | 2008-11-12 | — | — | CN | claimed |
| US-7208266-B2 | Endogenous coagulation activator compounds —use in exploring endogenous coagulation | SOCIETE DIAGNOSTICA-STAGO (FR) | 2007-04-24 | — | — | US | claimed |
| EP-1512323-B1 | Microbicidal composition based on formaldehyde donor compounds and antioxidants | AIR LIQUIDE SANTE INT (FR) | 2007-02-21 | — | — | EP | claimed |
| US-20050054642-A1 | Microbicidal composition based on formaldehyde donor compounds and antioxidants | SCHULKE & MAYR GMBH (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1512323-A1 | Microbicidal composition based on formaldehyde donor compounds and antioxidants | Air Liquide Santé (International) (FR) | 2005-03-09 | — | — | EP | claimed |
| CN-1460098-A | Activator for endogenetic pathway of coagulation and their use for exploring anomalies of coagulation | STAGO DIAGNOSTICA (FR) | 2003-12-03 | — | — | CN | claimed |
| US-20030157582-A1 | Endogenous coagulation activator compounds - use in exploring endogenous coagulation | SOCIETE DIAGNOSTICA-STAGO (FR) | 2003-08-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030157582-A1 | Endogenous coagulation activator compounds - use in exploring endogenous coagulation | TFPI, F2, F8 | SERPINE1 20/4885ESR1 1071/4885AKR1C4 3564/4885 |
| US-12559795-B2 | Compositions, methods, kits, cartridges, and systems for sequencing reagents | RNGTT, PHAX, RNMT | SERPINE1 2276/4885ESR1 3814/4885AKR1C4 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.